Deutsche Bank Initiates ProQR Therapeutics With Buy

Loading...
Loading...
Analysts at Deutsche Bank initiated coverage on ProQR Therapeutics
PRQR
with a Buy rating. The target price for ProQR Therapeutics is set to $32. ProQR Therapeutics' shares fell 4% to close at $12.48 yesterday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsDeutsche Bank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...